Kenmore, WA, United States of America

Zhonghua Hu

This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Qilu Puget Sound Biotherapeutics Corporation. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhonghua Hu. Retrieved from https://idiyas.com/inventor/zhonghua-hu-sta8806p

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Zhonghua Hu

Introduction

Zhonghua Hu is a prominent inventor based in Kenmore, WA (US). He has made significant contributions to the field of biotherapeutics, particularly in the development of antibodies for cancer treatment. With a total of 2 patents, his work is paving the way for innovative therapies that address critical health challenges.

Latest Patents

Zhonghua Hu's latest patents focus on Anti-PD1 and anti-CTLA4 antibodies. These patents describe anti-CTLA4 antibodies, anti-PD1 antibodies, and mixtures thereof, along with polynucleotides encoding such antibodies or mixtures. The methods of treatment utilizing these antibodies include applications in the treatment of cancer, infections, and immunodeficiency disorders. The specific sequences and properties of the anti-CTLA4 and anti-PD1 antibodies are also detailed in these patents.

Career Highlights

Zhonghua Hu is associated with Qilu Puget Sound Biotherapeutics Corporation, where he continues to advance his research and development efforts. His work is instrumental in creating innovative solutions for complex medical issues.

Collaborations

Zhonghua Hu collaborates with notable colleagues, including Zhi Liu and Wei Yan. Their combined expertise enhances the research and development initiatives at their organization.

Conclusion

Zhonghua Hu's contributions to the field of biotherapeutics, particularly through his patents on anti-PD1 and anti-CTLA4 antibodies, represent a significant advancement in cancer treatment. His ongoing work at Qilu Puget Sound Biotherapeutics Corporation continues to inspire innovation in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…